Sean Taasan, MD

University of Texas Southwestern Medical Center

Published Articles (2)

Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist

July 3, 2026

While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.

Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist

July 2, 2026

Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.